







an Open Access Journal by MDPI

Urologic Cancer: Endoscopic, Laparoscopic, and Robot-Assisted Surgery Managment

Guest Editor:

Dr. Kouii Izumi

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-8640, Ishikawa, Japan

Deadline for manuscript submissions:

1 March 2025

Message from the Guest Editor

Dear Colleagues,

The recent advances in robot-assisted urologic surgery have changed the quality of life for patients with urologic malignancy, such as prostate cancer, bladder cancer, and kidney cancer, with less invasive surgery, less blood loss, and better functional preservation. Importantly, the diagnostic value may also be changed by the recent developments in radical surgery. However, the impact of the development of such surgical modality is not fully assessed because of the paucity of data and short followup period. The comparison among radiologic, open, laparoscopic, and robot-assisted surgery has not been sufficiently investigated. Moreover, transurethral and endoscopic approaches to cancer lesions have also been developed in this decade. This Special Issue calls for clinical studies and reviews on any topic in "Endoscopic, Laparoscopic, and Robot-Assisted Surgery Management".

Dr. Kouji Izumi *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us